Last reviewed · How we verify
Peg-filgrastim
Peg-filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection.
Peg-filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection. Used for Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy after autologous bone marrow transplantation.
At a glance
| Generic name | Peg-filgrastim |
|---|---|
| Also known as | Neulastaᵀᴹ pfs inj. 6mg/0.6ml, pegylated filgrastim, PEG filgrastim, SD-01, Neulasta(R) |
| Sponsor | Asan Medical Center |
| Drug class | G-CSF agonist |
| Target | G-CSFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Peg-filgrastim works by binding to and activating the granulocyte colony-stimulating factor receptor (G-CSFR), which triggers the release of neutrophils from the bone marrow into the bloodstream. This helps to increase the number of neutrophils in the body, reducing the risk of infection in patients undergoing chemotherapy or other treatments that suppress the immune system.
Approved indications
- Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
- Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy after autologous bone marrow transplantation
Common side effects
- Bone pain
- Headache
- Nausea
- Injection site reaction
- Fatigue
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer (PHASE1, PHASE2)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (PHASE2)
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peg-filgrastim CI brief — competitive landscape report
- Peg-filgrastim updates RSS · CI watch RSS
- Asan Medical Center portfolio CI